The state of Texas has launched a formidable legal challenge against pharmaceutical giants Johnson & Johnson and its spinoff Kenvue, alleging they deliberately concealed the risks of Tylenol (acetaminophen) causing autism and ADHD when taken during pregnancy. This lawsuit intensifies an already volatile situation, adding significant pressure to Kenvue’s financial health and raising critical questions about corporate liability and product safety for long-term investors.
In a significant legal move that has sent ripples through the pharmaceutical industry, the state of Texas has initiated a lawsuit against Johnson & Johnson and its former consumer health unit, Kenvue. Filed on October 28, 2025, the suit alleges that the companies knowingly hid evidence linking acetaminophen, the active ingredient in Tylenol, to autism and attention deficit hyperactivity disorder (ADHD) in children whose mothers used the drug during pregnancy. This legal challenge underscores growing scrutiny over the popular pain reliever and its potential long-term implications for investors.
Unpacking the Allegations: Deception and Dishonesty
Texas Attorney General Ken Paxton, a Republican, did not mince words in his statement, claiming that “Big Pharma betrayed America by profiting off of pain and pushing pills regardless of the risks.” The lawsuit specifically accuses both Johnson & Johnson and Kenvue of deliberately withholding evidence that acetaminophen could be linked to neurodevelopmental disorders when consumed by pregnant women. This allegation strikes at the core of consumer trust and corporate responsibility.
Furthermore, the Texas lawsuit claims that the spin-off of Kenvue from Johnson & Johnson in 2023 was a calculated maneuver to shield the parent company from potential liability arising from Tylenol’s alleged risks. This “fraudulent transfer” claim suggests a sophisticated strategy to insulate assets, adding another layer of complexity to the legal battle. According to Reuters, Johnson & Johnson sold Tylenol for over six decades before Kenvue took over in 2023. This long history ties the product directly to both entities.
The Defendants’ Stance: Safety First, Misinformation Concerns
In response to the allegations, Kenvue has strongly defended the safety of its medication, asserting that the claims are baseless. The company highlighted that both pain and fevers during pregnancy can pose significant dangers to children, implying the importance of effective and safe treatments like Tylenol. “Acetaminophen is the safest pain reliever option for pregnant women as needed throughout their entire pregnancy,” Kenvue stated, expressing deep concern over the “perpetuation of misinformation” regarding acetaminophen’s safety. This firm defense indicates a prolonged legal fight.
Johnson & Johnson, while not directly commenting on the lawsuit’s specifics, issued a separate statement emphasizing that Kenvue is now responsible for “all rights and liabilities associated with the sale of its over-the-counter products, including Tylenol.” This stance aligns with the alleged strategy of using the spin-off to create a legal buffer, a point of contention for Texas prosecutors.
Political Echoes and Broader Scientific Debates
The lawsuit’s timing comes just weeks after President Donald Trump made unproven claims that Tylenol causes autism in children, a link that lacks scientific backing. Paxton’s lawsuit notably referenced Trump’s public statements and a Truth Social post where the president urged pregnant women to avoid Tylenol unless “absolutely necessary.” This political backdrop adds a layer of public visibility and ideological framing to the legal proceedings, though the scientific community maintains a cautious stance on causation. Autism has also been a longstanding concern of U.S. Health and Human Services Secretary Robert F. Kennedy Jr., whose agency oversees the FDA.
The debate is not entirely without scientific context. Last month, the U.S. Food and Drug Administration (FDA) indicated it would consider seeking new warning labels for acetaminophen to reflect potential links to neurodevelopmental disorders. This move, while not a definitive confirmation of causation, signals an increasing level of scrutiny from regulatory bodies, a development that investors should watch closely.
A Web of Legal Challenges: Beyond Texas
The Texas lawsuit is not an isolated incident. It is part of a broader legal landscape facing Tylenol’s manufacturers. Hundreds of private lawsuits have been filed by families alleging that their children developed autism or ADHD after maternal Tylenol use during pregnancy. While a judge dismissed many of these cases last December, an appeal is scheduled to be heard by a federal appeals court in Manhattan on November 17, representing continued legal pressure on the companies. The law firm Keller Postman, representing families in the federal appeal, is also collaborating with Paxton on the Texas lawsuit.
Johnson & Johnson’s experience with product liability extends beyond Tylenol. The company is currently facing more than 73,000 lawsuits from plaintiffs who claim they developed cancer from its baby powder and other talc products. Efforts by Johnson & Johnson to resolve these cases through bankruptcy have been rejected by federal courts three times. This history of substantial legal challenges adds context to the company’s approach to managing liability, especially concerning the Kenvue spin-off. Concerns about Tylenol’s safety gained significant traction only after Johnson & Johnson announced the Kenvue spinoff in 2021, according to filings reviewed by Reuters.
Investment Implications: What This Means for Your Portfolio
For investors, the Texas lawsuit introduces significant uncertainty and risk for both Kenvue and Johnson & Johnson. Shares of Kenvue, which generates substantial revenue from Tylenol, fell as much as 2.4% in morning trading following the news, and had previously dropped 7.5% on September 22 when President Trump first discussed Tylenol and autism. Johnson & Johnson also experienced a decline, falling as much as 1.6%. These immediate market reactions highlight investor sensitivity to the potential financial repercussions.
The long-term implications are multi-faceted:
- For Kenvue: As the direct seller of Tylenol since 2023, Kenvue faces direct exposure to legal costs, potential large settlements or judgments, and significant brand reputation damage. This adds to existing challenges, including falling sales since its spin-off and activist investor pressures that led to the ouster of its former CEO. The outcome of these lawsuits could significantly impact Kenvue’s profitability and growth trajectory.
- For Johnson & Johnson: While J&J aims to shield itself from liability through the Kenvue spin-off, the “fraudulent transfer” claim directly challenges this strategy. A successful challenge could expose Johnson & Johnson to billions in potential liabilities. Even without direct liability, the ongoing negative publicity associated with a former flagship product could affect its overall brand image and investor confidence. The company’s history with talc lawsuits demonstrates its vulnerability to product liability claims, a factor investors must consider. According to its investor relations information, Johnson & Johnson has a clear focus on its pharmaceutical and medical device businesses, making consumer health liabilities particularly undesirable.
- Broader Market Impact: The legal scrutiny on acetaminophen could set precedents for other common over-the-counter medications, prompting increased regulatory oversight and potential re-evaluations of product safety claims across the industry.
Investors should monitor the progression of the Texas lawsuit, the federal appeals for private cases, and the FDA’s decisions regarding warning labels. The outcome of these legal and regulatory actions will provide crucial insights into the future financial health of Kenvue and the extent of Johnson & Johnson’s insulation from product liability risks.
